Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

Szeto HH. British Journal of Pharmacology 2014

Document identifier
CEI-BR-105
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Szeto HH
Title
First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
Source
British Journal of Pharmacology
Year
2014
Volume, issue, pages
171(8):2029–2050
Digital object identifier
10.1111/bph.12461
PubMed identifier
24117165
Record type
Journal article
Institute identifier
CEI-BR-105

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

§1.3Subject tags

ss-31 elamipretide mitochondria

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.